Johnson & Johnson (J&J) delivered a quarterly earnings beat, powered by surging sales of its autoimmune drug Tremfya, and reiterated its commitment to spinning off its DePuy Synthes orthopedics business on a mid-2027 timeline. The news underscores the healthcare giant's strategy to focus on higher-growth pharmaceutical and medtech segments while shedding slower-moving units.
Tremfya's strong quarter
Tremfya, a treatment for plaque psoriasis and psoriatic arthritis, saw sales jump 68% to $2.4 billion in the quarter. The drug has become a key growth driver for J&J, as it competes in the lucrative immunology market against rivals like AbbVie's Humira and newer entrants. The robust performance helped J&J beat Wall Street's profit expectations, even as the company navigates patent expirations and pricing pressures in other parts of its portfolio.
The strong showing from Tremfya is part of a broader trend in the pharmaceutical industry, where companies are leaning on specialty drugs for chronic conditions to offset declining revenue from older blockbusters. For J&J, the drug's momentum provides a cushion as it prepares for the eventual loss of exclusivity on other products.
DePuy Synthes spinoff: what it means
J&J first announced plans to separate its orthopedics division, which includes the DePuy Synthes brand, in 2023. The unit makes joint replacements, trauma products, and surgical instruments. The company now says it is still aiming for a mid-2027 separation, reaffirming its earlier guidance.
Spinning off DePuy Synthes would create a standalone, publicly traded company focused solely on orthopedics. For J&J, the move is designed to streamline operations and allow each business to pursue its own strategy and capital allocation. For investors, a spinoff can unlock value by giving the market a clearer view of the separate businesses' financials and growth prospects.
Orthopedics has been a challenging area for J&J, with sales pressured by supply chain issues, softer demand for elective procedures, and competitive pricing. By separating the unit, J&J aims to sharpen its focus on faster-growing areas like pharmaceuticals and medical devices, including surgical robotics and cardiovascular products.
What it means for investors
For everyday investors, the earnings beat and the reaffirmed spinoff timeline offer a few takeaways. First, J&J's pharmaceutical segment remains a reliable growth engine, with Tremfya leading the way. Second, the planned spinoff could create a new investment opportunity: when the separation occurs, shareholders of J&J will likely receive shares in the new orthopedics company, similar to how other large healthcare firms have handled spinoffs.
However, spinoffs also come with risks. The new company will inherit the challenges of the orthopedics market, including competition and pricing pressure. Investors should also watch for any changes to the timeline, as corporate separations can be delayed by regulatory approvals or market conditions.
J&J's results come amid a busy earnings season for healthcare and other sectors. Earlier this week, UnitedHealth raised its 2026 profit outlook after beating third-quarter expectations, and bank earnings are in focus as chip weakness drags Nasdaq futures. These reports provide a snapshot of how different industries are faring in the current economic environment.
For J&J, the next key milestones will be continued Tremfya growth, progress on the spinoff, and any updates on its pipeline of new drugs. Investors will also be watching how the company manages its overall debt and cash flow, especially as it prepares to fund the separation.
As always, it's important to remember that past performance is not a guarantee of future results. While Tremfya's surge is encouraging, the pharmaceutical industry faces ongoing headwinds from drug pricing reform and patent cliffs. The spinoff, if completed as planned, could reshape J&J's investment profile, but it's still a few years away.
In the meantime, J&J's earnings beat and reaffirmed guidance provide a measure of stability for shareholders. The company's diversified portfolio—spanning pharmaceuticals, medical devices, and consumer health—continues to be a defensive play in many portfolios, even as it undergoes strategic shifts.
